Dose Optimization in Kidney Disease: Opportunities for PBPK Modeling and Simulation

Area of Science:

• Pharmacology
• Nephrology
• Computational Biology

Background:

• Kidney disease alters drug pharmacokinetic (PK) profiles, affecting both renally and non-renally cleared drugs.
• Understanding these PK changes is crucial for effective drug dose optimization in patients with kidney impairment.
• The roles of drug transporters and metabolic enzymes in altered drug disposition during kidney disease progression require further elucidation.

Purpose of the Study:

• To highlight the essential role of pharmacokinetic alterations in kidney disease.
• To emphasize the utility of physiologically based pharmacokinetic (PBPK) modeling for dose optimization in kidney impairment.
• To discuss how PBPK approaches can integrate preclinical and clinical data for mechanistic insights.

Main Methods:

• Review of existing literature on kidney disease and drug pharmacokinetics.
• Discussion of the application of physiologically based pharmacokinetic (PBPK) modeling and simulation.
• Integration of knowledge from preclinical and clinical research using PBPK.

Main Results:

• Kidney disease impacts the disposition of a wide range of drugs, not just those cleared by the kidneys.
• PBPK modeling provides a mechanistic framework to understand and predict drug exposure changes in kidney disease.
• PBPK can facilitate dose adjustment, toxicity reduction, and identification of interindividual variability.

Conclusions:

• Physiologically based pharmacokinetic (PBPK) modeling is a powerful tool for optimizing drug dosage in kidney disease.
• PBPK facilitates a priori prediction of drug exposures and aids in identifying sources of variability.
• Regulatory guidances support the use of PBPK in model-based dose-finding research for kidney impairment.